1
SECURITIES AND EXCHANGE COMMISSION
450 Fifth Street, N.W.
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report: October 11, 1995
Atrix Laboratories, Inc.
--------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
Delaware 0-18231 84-1043826
- ------------------- ------------------- ------------------
(State of (Commission (IRS Employer
incorporation) File Number) Identification No.)
2579 Midpoint Drive, Fort Collins, Colorado 80525
----------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (970) 482-5868
Not Applicable
--------------
(Former Name or Former Address, if Change Since Last Report)
2
Item 5. Other Events.
See the Press Release attached hereto as Exhibit 20.
Item 7. Financial Statements and Exhibits.
(c) Exhibits
20 Press Release dated October 11, 1995 regarding the results
of a one year pivotal study on Atrix Laboratories, Inc.'s
ATRISORB(TM) Guided Tissue Regeneration (GTR) product.
3
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
ATRIX LABORATORIES, INC.
Date: October 20, 1995 By: /s/ Kimberly A. Marks
---------------------------------------
Kimberly A. Marks, Corporate Controller
4
EXHIBIT INDEX
Exhibit No. Exhibit Description Page
----------- ------------------- ----
20 Press Release dated October 11, 1995 regarding
the results of a one year pivotal study on Atrix
Laboratories, Inc.'s ATRISORB(TM) Guided
Tissue Regeneration (GTR) product.